Jaguar Health Inc Stock Price, News & Analysis

Jaguar Health (NASDAQ:JAGX) announced the commercial availability of Canalevia-CA1, the first FDA-approved treatment for chemotherapy-induced diarrhea (CID) in dogs. Following its conditional approval on December 21, 2021, this oral medication is now accessible through leading veterinary distributors in the U.S. The company highlights the unmet need for such a treatment, as over half of surveyed veterinarians noted CID disrupts cancer treatment in dogs. Canalevia-CA1, using the plant-based active ingredient crofelemer, aims to enhance dogs' comfort during chemotherapy.

Jaguar Health, Inc. (NASDAQ:JAGX) announced that its CEO, Lisa Conte, will present at NobleCon18 on April 21, 2022, at 11:00 AM Eastern at the Hard Rock Hotel & Casino in Hollywood, Florida. Attendees can meet management during a breakout session at 10:00 AM. Registration for this investor conference is free via the provided link. A video of the presentation will be available the next day on Noble Capital Markets' website and archived for 90 days. Jaguar focuses on sustainable, plant-based medicines for gastrointestinal issues.

Jaguar Health (NASDAQ:JAGX) has announced the replenishment of its New Employee Inducement Award Plan with 471,833 shares of common stock, effective June 16, 2020. This addition is on top of 500,000 shares registered previously on May 28, 2021. The plan aims to grant equity awards to new hires or former employees, serving as an inducement for their employment as per Nasdaq Listing Rule 5635(c)(4).

Jaguar focuses on developing plant-based, non-opioid pharmaceuticals for gastrointestinal issues.

Jaguar Health (NASDAQ:JAGX) announces a dinner event for U.S. veterinary oncologists on April 12, 2022, in Puerto Vallarta, Mexico, coinciding with the Veterinary Cancer Society (VCS) Mid-Year Conference. The dinner will focus on chemotherapy-induced diarrhea (CID) treatment in dogs, featuring a private chef and entertainment. Canalevia-CA1 (crofelemer), the first FDA conditionally approved treatment for CID in dogs, will be showcased at the conference. The VCS Mid-Year Conference runs from April 9-12, 2022, at the Marriott Puerto Vallarta Resort & Spa.

Jaguar Health, Inc. has appointed Pravin Chaturvedi, PhD, as Chief Scientific Officer and Chair of the Scientific Advisory Board. Dr. Chaturvedi, with over 30 years in the pharmaceutical industry, will lead two key crofelemer pipeline development activities over the next 12-15 months. These include the Phase 3 OnTarget trial for cancer therapy-related diarrhea and collaborations for rare diseases like short bowel syndrome. Both initiatives aim to expand patient access and enhance Jaguar's market position, with completion expected soon.

Jaguar Health has entered a strategic agreement with Quadri Pharmaceuticals Store granting exclusive promotional, commercialization, and distribution rights for crofelemer in multiple Middle Eastern countries, including Saudi Arabia and the UAE. This agreement covers human indications approved in the U.S., specifically targeting HIV-related and cancer therapy-related diarrhea. The partnership aims to enhance access to crofelemer, which is currently undergoing a pivotal Phase 3 clinical trial. This initiative is crucial due to the rising HIV statistics in the region, highlighting the growing demand for effective treatments.

Jaguar Health, Inc. (NASDAQ:JAGX) announced a recorded investor webcast on March 14, 2022, sharing company updates and 2021 financial results. Key initiatives include the ongoing OnTarget Phase 3 clinical trial for crofelemer, focused on preventing cancer therapy-related diarrhea. The company reported Mytesi net revenue of approximately $2.1 million in Q4 2021, a significant increase of 230% from Q3 2021. Additionally, Jaguar received FDA conditional approval in December 2021 for Canalevia™-CA1 treating chemotherapy-induced diarrhea in dogs.

Jaguar Health provided a comprehensive update on its progress during 2021, highlighting critical milestones in the development of its plant-based drug pipeline. Key achievements include the ongoing OnTarget Phase 3 clinical trial for crofelemer, FDA conditional approval for Canalevia-CA1 for chemotherapy-induced diarrhea in dogs, and a significant revenue increase for Mytesi, which saw net revenues of approximately $2.1 million in Q4 2021, marking a 230% increase from Q3 2021. Despite these advances, the company reported a substantial net loss of $52.6 million for 2021.

Jaguar Health (NASDAQ:JAGX) has announced an investor webcast scheduled for March 14, 2022, at 8:30 AM ET to discuss its Q4 2021 financials and corporate updates. The company plans to file its Annual Report on March 11, 2022, for the fiscal year ending December 31, 2021. Jaguar focuses on developing plant-based, non-opioid prescription medicines for gastrointestinal distress. Their crofelemer drug candidate is being evaluated in a pivotal Phase 3 clinical trial. For more information, visit jaguar.health.